Lyra Therapeutics MACD Death Cross and Bearish Marubozu on 15-minute chart.

According to Lyra Therapeutics's 15-minute chart, a MACD Death Cross and Bearish Marubozu pattern was observed on August 20, 2025 at 13:00. This indicates that the stock price has the potential to continue declining, with sellers dominating the market and bearish momentum likely to persist.

On August 20, 2025, at 13:00, Lyra Therapeutics' 15-minute chart exhibited a MACD Death Cross and a Bearish Marubozu pattern, signaling potential market decline. This technical analysis suggests that the stock price may continue to drop, with sellers dominating the market and bearish momentum likely to persist [1].

Lyra Therapeutics Inc. (LYRA) has been experiencing significant market volatility, as indicated by a bearish trend in its 15-minute chart. On August 15, 2025, at 10:00, the stock exhibited a MACD Death Cross and a Bearish Marubozu pattern, suggesting a potential decline in its stock price. These technical indicators signal that sellers are currently in control of the market, and the bearish momentum is likely to continue [2].

The company reported its fiscal 2025 second-quarter earnings on August 12, 2025, showing a notable improvement in its financial performance. Lyra Therapeutics narrowed its Q2 2025 net loss by 84.5% to $7.44 million, reducing its earnings per share (EPS) loss by 85.0% to $5.51. Despite these improvements, the company continues to report losses, having posted net losses in the corresponding quarter for four consecutive years [1].

The sharp decline in total revenue, dropping by 69.4% to $183,000 in Q2 2025, was primarily driven by a drop in collaboration revenue, which stood at $183,000, representing the company’s sole source of income in the quarter. The stock price of Lyra Therapeutics edged up 2.12% on the latest trading day but declined by 21.92% month-to-date as of the report date [1].

CEO Maria Palasis, Ph.D., noted that the positive ENLIGHTEN 2 Phase 3 results have enabled Lyra to secure financing and drive momentum for regulatory strategy optimization and resumption of manufacturing. She emphasized LYR-210’s potential as a six-month treatment for chronic rhinosinusitis (CRS) and noted ongoing analysis of the ENLIGHTEN 1 and 2 datasets to inform business strategy. Palasis expressed cautious optimism about LYR-210’s potential to benefit patients while acknowledging the need to align with the FDA for a potential NDA submission [1].

Lyra expects its cash and cash equivalents of $29.8 million as of June 30, 2025, to fund operations into the third quarter of 2026. The company anticipates using proceeds from a recent $5.0 million financing, plus up to $9.8 million if private placement warrants are exercised, for working capital, clinical development, and manufacturing. Lyra is preparing for a Type C meeting with the FDA in the second half of 2025 to align on the path forward for an NDA submission for LYR-210 in patients without nasal polyps [1].

The recent technical indicators and financial performance suggest that Lyra Therapeutics may face challenges in the coming quarters. Investors should closely monitor the company's earnings report and market conditions to make informed decisions. The volatility in the stock price and the company's financial performance highlight the need for investors to stay vigilant and assess the potential risks and opportunities associated with Lyra Therapeutics [2].

References:
[1] https://www.ainvest.com/news/lyra-therapeutics-2025-q2-earnings-significant-loss-reduction-2508/
[2] https://www.ainvest.com/news/lyra-therapeutics-15min-chart-shows-kdj-death-cross-bearish-marubozu-pattern-2508/